Research programme: ligand activated therapeutics - KemPharm

Drug Profile

Research programme: ligand activated therapeutics - KemPharm

Alternative Names: KP 214; KP 515; KP 606; KP 612; KP 746; KP303; KP606/IR; KP7xx

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KemPharm
  • Class Dibenzothiazepines; Morphine derivatives; Opioid peptides; Phenylacetates; Piperazines; Piperidines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Opioid receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute pain; Cardiovascular disorders; CNS disorders; Pain

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for research development in CNS-disorders in USA (PO)
  • 23 Jan 2018 KemPharm has patent protection for KP 606 entitled "Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof" in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute pain in USA (PO, Immediate release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top